|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 120.05 INR | 0.00% |
|
-4.30% | +66.99% |
| 05-21 | Dubai Investments says Globalpharma signs 7 strategic MoUs | RE |
| 05-20 | ZIM Laboratories Limited, Q4 2026 Earnings Call, May 20, 2026 |
Company Valuation: ZIM Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,178 | 2,596 | 3,528 | 4,653 | 3,908 | 3,203 |
| Change | - | 120.48% | 35.88% | 31.91% | -16.02% | -18.03% |
| Enterprise Value (EV) 1 | 1,987 | 3,095 | 4,085 | 5,672 | 5,065 | 4,066 |
| Change | - | 55.76% | 31.98% | 38.85% | -10.7% | -19.73% |
| P/E | 16.1x | 17.8x | 14.5x | 27x | 32.1x | 50.3x |
| PBR | 0.73x | 1.48x | 1.76x | 1.95x | 1.55x | 1.08x |
| PEG | - | 0.2x | 0.2x | -0.9x | -1.1x | -1x |
| Capitalization / Revenue | 0.38x | 0.78x | 0.89x | 1.27x | 1.03x | 0.86x |
| EV / Revenue | 0.65x | 0.93x | 1.02x | 1.54x | 1.34x | 1.09x |
| EV / EBITDA | 5.22x | 7.98x | 8.19x | 14.5x | 12.8x | 16.4x |
| EV / EBIT | 8.26x | 12.4x | 11.6x | 22.1x | 20.6x | 39.5x |
| EV / FCF | 18.5x | 12.8x | -29.3x | -8.48x | -30.4x | -26.5x |
| FCF Yield | 5.41% | 7.81% | -3.41% | -11.8% | -3.29% | -3.78% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 1.5 | 2.986 | 5.01 | 3.539 | 2.497 | 1.19 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,073 | 3,335 | 3,986 | 3,675 | 3,791 | 3,744 |
| EBITDA 1 | 381 | 387.9 | 499 | 390.6 | 395.6 | 248.4 |
| EBIT 1 | 240.6 | 250.3 | 352.6 | 256.7 | 245.7 | 103 |
| Net income 1 | 73.18 | 145.5 | 244.3 | 172.5 | 121.7 | 58.38 |
| Net Debt 1 | 809.6 | 498.9 | 557.4 | 1,019 | 1,158 | 863.1 |
| Reference price 2 | 24.17 | 53.28 | 72.40 | 95.50 | 80.20 | 59.87 |
| Nbr of stocks (in thousands) | 48,726 | 48,726 | 48,726 | 48,726 | 48,726 | 53,500 |
| Announcement Date | 08/09/21 | 26/08/22 | 16/06/23 | 05/06/24 | 03/06/25 | 05/06/26 |
1INR in Million2INR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 66.38M | |
| 35.81x | 6.76x | 23.37x | 0.81% | 48.41B | |
| 17.97x | 2.03x | 9.59x | 1.33% | 34.99B | |
| 27.22x | 3.3x | 17.11x | 0.84% | 11.62B | |
| 26.4x | 3.9x | 15.87x | 0.6% | 11.47B | |
| 19.11x | 3.34x | 11.98x | 3.48% | 8.99B | |
| 15.88x | 2.04x | 6.86x | 3.27% | 6.88B | |
| 8.14x | 1.9x | 4.98x | 5.33% | 6.62B | |
| 33.47x | 3.81x | 16.2x | 0.24% | 6.43B | |
| Average | 23.00x | 3.39x | 13.25x | 1.99% | 15.05B | |
| Weighted average by Cap. | 26.08x | 4.16x | 15.80x | 1.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ZIMLAB Stock
- Valuation ZIM Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
